Compare Amylx Pharmaceuticals Inc (AMLX) vs Warner Music Group Corp (WMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Warner Music Group Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Warner Music Group Corp trades at $28.82 (market cap $15.12B). The key difference: Warner Music Group Corp is far larger — about 7.6× Amylx Pharmaceuticals Inc's market cap, and Warner Music Group Corp pays a 2.62% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | WMG | |
|---|---|---|
Market Cap | $1.98B | $15.12B |
Sector | Health | Media |
52-Week High | $18.70 | $34.72 |
52-Week Low | $7.64 | $23.65 |
Enterprise Value | $1.70B | $19.32B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Warner Music Group (WMG) trades at $28.99, down 0.51% on the day, with a bullish technical signal driven by moving averages but mixed oscillators. The company reported revenue growth to $6.71B in 2025, though net income margin declined to 5.44%. Recent acquisitions like Sureel AI highlight strategic moves in AI-driven music attribution. Analyst consensus is strongly bullish with a $40.40 price target, implying significant upside from current levels.
WMG presents a compelling growth story with solid revenue expansion and strategic AI investments, but faces risks from margin compression and competitive pressures. The stock's high P/E of 34.51 suggests premium valuation, yet strong analyst buy ratings and institutional interest support further upside potential if execution on catalog monetization and streaming growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
